This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...
The findings add to evidence that the company’s drug, obicetrapib, could change the narrative surrounding a once-abandoned ...
NewAmsterdam Pharma's obicetrapib demonstrates strong phase 3 results. Discover why NAMS stock could rise as further studies ...
NewAmsterdam Pharma said Tuesday its cholesterol drug lowered the risk of major cardiovascular events and the biotech stock ...
Dutch clinical-stage drug developer NewAmsterdam Pharma saw its shares close up 41% at $26.19 yesterday on positive research ...
During the last three months, 5 analysts shared their evaluations of NewAmsterdam Pharma NAMS, revealing diverse outlooks ...
NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) has earned an average recommendation of “Buy” from the six research firms ...
NewAmsterdam Pharma said Tuesday its cholesterol drug lowered the risk of major cardiovascular events and the biotech stock ...
NewAmsterdam Pharma Company N.V. (NAMS), a late-stage, clinical biopharmaceutical company, Tuesday announced positive topline data ...